KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Divestments (2020 - 2023)

Bio-Rad Laboratories has reported Divestments over the past 3 years, most recently at $2.5 million for Q4 2023.

  • Quarterly Divestments rose 6150.0% to $2.5 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2023, up 6250.0% year-over-year, with the annual reading at $2.5 million for FY2023, 78.57% up from the prior year.
  • Divestments was $2.5 million for Q4 2023 at Bio-Rad Laboratories, up from $40000.0 in the prior quarter.
  • Over five years, Divestments peaked at $12.2 million in Q2 2020 and troughed at $40000.0 in Q4 2022.
  • The 3-year median for Divestments is $2.5 million (2023), against an average of $4.9 million.
  • The largest YoY upside for Divestments was 6150.0% in 2023 against a maximum downside of 6150.0% in 2023.
  • A 3-year view of Divestments shows it stood at $12.2 million in 2020, then plummeted by 99.67% to $40000.0 in 2022, then surged by 6150.0% to $2.5 million in 2023.
  • Per Business Quant, the three most recent readings for BIO's Divestments are $2.5 million (Q4 2023), $40000.0 (Q4 2022), and $12.2 million (Q2 2020).